Bespak helps develop three new products for Beximco

Products developed using Bespak's Metered Dose Inhaler (MDI) optimisation services have recently been launched in Bangladesh by Beximco Pharmaceuticals Ltd.

Products developed using Bespak's Metered Dose Inhaler (MDI) optimisation services have recently been launched in Bangladesh by Beximco Pharmaceuticals Ltd.

All three products; Azmasol HFA, Decomit 50 HFA and Decomit 100 HFA, employ a Bespak valve and actuator and are aimed at patients with respiratory illnesses such as asthma. Azmasol, as a reliever medication, uses a Salbutamol formulation, whereas both the Decomit products act as preventative medication, using a Beclometasone Dipropionate (BDP) formulation.

Through its rigorous optimisation service, Bespak offers expertise in managing the complex relationship between valve, actuator, formulation and drug pack, providing an optimised device development process for existing, novel and conceptual devices.

Bespak Commercial Director, Jay Bhogaita said: At Bespak we understand the importance of successfully pairing a drug with its delivery device and how fundamental this is in the safety and efficacy of the product and ultimately its commercial success. By utilising the expertise and skills of our scientists we are able to develop individual formulation and device designs much faster than through a trial and error approach..


Companies